Trading-Stocks.de

Amgen raises dividend by 10%

Amgen Inc. AMGN, -3.80% said late Friday its board of directors has declared a dividend of $1.45 a share for the first quarter of 2019. The dividend is payable March 8 to shareholders of record on Feb. 15. That represents a 10% increase from what Amgen paid in each of the previous four quarters. Shares of Amgen rose 0.2% in the extended session Friday after ending the regular trading day down 3.8%.

...

https://www.marketwatch.com/story/amgen-...2018-12-07

Nicht das es eine Rolle spielt, aber das sind "nur" 9,8 % Erhöhung -
ich habe die auch seit ca. einem Jahr und wundere mich die letzten
Tage auch über den Rückgang, geht aber allen Pharmawerten so,...

Nachtrag - ist auch die zweite Erhöhung in diesem Jahr, ich glaube auf $ Basis waren das 36 % Erhöhung
dieses Jahr

Amgen Stock Falls After Hours on Light Forecast Despite Good Quarterly Earnings

Drugmaker reports $3.42 in fourth-quarter earnings per share, beating analyst estimates.

The California-based biotech giant lost some 2.6% to $187.10 shortly after 6 p.m. ET.

...

Amgen returned to those losing ways in after-hours action Tuesday after the company projected 2019 full-year revenues at $21.8 billion to $22.9 billion and earnings per share at $13.10 to $14.30. That fell below analysts' previous expectations.

...

All told, the company earned $3.42 per share in the quarter -- an 18% jump from the same period a year earlier. That beat analysts' consensus estimates of $3.26 in EPS, according to Zacks Investment Research. Operating income also increased 6% to $2.7 billion, while total product sales jumped 8% year over year.

For 2018 as a whole, Amgen earned $14.40 in EPS, a 14% rise from 2017. Operating income also gained 2% to $11.9 billion, while total 2018 product sales grew 3%.

...

https://www.thestreet.com/investing/earn...yptr=yahoo

Amgen stock rises on company's earnings beat, Neulasta sales fall 12%

...

Amgen said it earned $2 billion, or $3.18 a share, in the quarter, compared with $2.3 billion, or $3.25 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $3.56 a share, compared with $3.47 a share a year ago. Revenue was flat at $5.6 billion. 

...

https://www.marketwatch.com/story/amgen-...yptr=yahoo

Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D

Amgen AMGN reported third-quarter 2019 earnings of $3.66 per share, which beat the Zacks Consensus Estimate of $3.51. Earnings declined 1% year over year due to lower revenues and operating profits.

Total revenues of $5.74 billion in the quarter beat the Zacks Consensus Estimate of $5.63 billion. However, total revenues declined 3% year over year.


...

https://finance.yahoo.com/news/amgen-amg...03680.html

Ex-Dividend-Date 14.11., Auszahlung am 06.12.
d.h. heute ist letzter Tag für Dividende im Dezember
Dividendensumme 1,45$ Kurs 221$ Dividendenrendite vor Steuern 2,6%

Amgen erhöht nach Abschluss von Zukauf erneut die Jahresprognose

...

Der Umsatz dürfte nun zwischen 23,1 und 23,3 Milliarden US-Dollar liegen, teilte das Unternehmen am Donnerstag in Thousand Oaks mit. Vorher standen 22,8 bis 23,0 Milliarden Dollar im Plan. Der bereinigte Gewinn je Aktie dürfte ebenso profitieren und mit 14,50 bis 14,70 Dollar höher ausfallen als bisher mit 14,20 bis 14,45 Dollar veranschlagt.

...

https://www.finanzen.net/nachricht/aktie...se-8250194

Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates

Amgen (AMGN) came out with quarterly earnings of $3.64 per share, beating the Zacks Consensus Estimate of $3.44 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 5.81%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $3.51 per share when it actually produced earnings of $3.66, delivering a surprise of 4.27%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Amgen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.20 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 3.18%. This compares to year-ago revenues of $6.23 billion.


...

https://finance.yahoo.com/news/amgen-amg...10597.html

Zitat:UPDATE 2-Amgen patents on top-selling arthritis drug Enbrel upheld, shares rise
(Adds comments, details from decision, background, case
citation, byline)
By Jonathan Stempel
July 1 (Reuters) - A U.S. appeals court on Wednesday upheld
two patents for Amgen Inc's multibillion-dollar
rheumatoid arthritis drug Enbrel in a defeat for Novartis AG
, which has been trying to sell its own version.
The 2-1 decision by the U.S. Federal Circuit Court of
Appeals in Washington, D.C. gives Amgen 31 years of exclusive
rights to Enbrel, with protection for the patents extending to
November 2028 and April 2029.
Sandoz, a unit of Switzerland-based Novartis, said it may
ask the U.S. Supreme Court to review the decision, which upheld
an August 2019 ruling by a federal judge in New Jersey.
In early afternoon trading, Amgen shares were up $16.28, or
6.9%, at $252.14 on the Nasdaq.
Enbrel is Amgen's largest drug, generating $5.23 billion, or
22%, of the company's $23.4 billion of revenue in 2019.
Launched in 1998, Enbrel is used to treat adults with
moderate to severe active rheumatoid arthritis.
Amgen's patents cover etanercept, an active ingredient in
Enbrel, and a process to make that protein. Enbrel was developed
by Immunex Corp, which Amgen acquired in 2002.
Sandoz had won U.S. regulatory approval in 2016 for a
"biosimilar" version of Enbrel, known as Erelzi, but has been
unable to sell it in the United States.
The Novartis unit argued that Amgen's patents described
concepts contained in previous patents and should therefore be
invalidated because they were "obvious."
But the appeals court said Sandoz's argument amounted to
"merely disagreements with the district court's weighing of the
evidence."
U.S. District Judge Claire Cecchi in Newark, New Jersey, had
upheld the patents' validity. [nL4N2554VW]
Michael Yee, a Jefferies analyst who rates Amgen "buy," said
Wednesday's decision removed a "key overhang" for Amgen, likely
freeing it from imminent competition for Enbrel.
Amgen is based in Thousand Oaks, California, while Novartis
has offices in East Hanover, New Jersey.
The Federal Circuit handles intellectual property appeals.
The case is Immunex Corp et al v Sandoz Inc et al, U.S.
Federal Circuit Court of Appeals, No. 20-1037.

(Reporting by Jonathan Stempel in New York; Additional
reporting by Lewis Krauskopf in New York and Jan Wolfe in
Washington, D.C.; Editing by Bill Berkrot and Dan Grebler)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters
Messaging: jon.stempel.thomsonreuters.com@reuters.net))